Cargando…

Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China

Background: Lopinavir/ritonavir (LPV/r) is a major antiretroviral treatment in China, but little is known about the performance of first-line LPV/r-based regimen in treatment-naïve patients with human immunodeficiency virus type 1 (HIV-1) infection. This study aims to assess the efficacy and adverse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Bin, Wang, Yin, Zhou, Ruifeng, Jiang, Taiyi, Zhang, Hongwei, Li, Zaicun, Liu, An, Shao, Ying, Hua, Wei, Zhang, Tong, Wu, Hao, He, Shenghua, Dai, Lili, Sun, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920196/ https://www.ncbi.nlm.nih.gov/pubmed/31920659 http://dx.doi.org/10.3389/fphar.2019.01472

Ejemplares similares

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
por: Marima, Rahaba, et al.
Publicado: (2020)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy
por: Vesterbacka, Jan, et al.
Publicado: (2013)

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
por: Ye, Linhu, et al.
Publicado: (2021)

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy
por: Banda, Clifford G., et al.
Publicado: (2018)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
por: Huang, Yin-Qiu, et al.
Publicado: (2020)

Safety and Tolerability of High Dose Atazanavir–Ritonavir and Lopinavir–Ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
por: Russo, Vincenzo, et al.
Publicado: (2020)

Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Naïve HIV-Infected Patients in China: A Prospective Cohort Study
por: Hua, Wei, et al.
Publicado: (2021)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison
por: Gagliardini, Roberta, et al.
Publicado: (2021)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
por: Huang, Chang, et al.
Publicado: (2023)

Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials
por: Huang, Xiaojie, et al.
Publicado: (2015)

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19
por: Karolyi, Mario, et al.
Publicado: (2021)

The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment
por: Skinner-Adams, Tina S., et al.
Publicado: (2012)

Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam
por: Lan, Nguyen Thi Ngoc, et al.
Publicado: (2014)

The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
por: Kredo, T., et al.
Publicado: (2016)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
por: Greffrath, Wilhelm P., et al.
Publicado: (2018)

Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
por: Gleason, Rudolph L., et al.
Publicado: (2015)

miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir
por: Bresciani, Elena, et al.
Publicado: (2019)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
por: Karolyi, M., et al.
Publicado: (2022)

Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China
por: Guo, Peng-Le, et al.
Publicado: (2021)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years
por: Lima, Viviane D, et al.
Publicado: (2014)

Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis
por: Tigabu, Bereket Molla, et al.
Publicado: (2020)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
por: Clumeck, Nathan, et al.
Publicado: (2014)

Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
por: Huang, Yinqiu, et al.
Publicado: (2018)

Costs of Care of HIV-Infected Children Initiating Lopinavir/Ritonavir-Based Antiretroviral Therapy before the Age of Two in Cote d’Ivoire
por: Desmonde, Sophie, et al.
Publicado: (2016)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_8iubhphgr1b5s8s4249sd85tm0